Literature DB >> 34301737

Pharmacokinetics of Remdesivir and GS-441524 during PIRRT and Seraph 100 Therapy.

Julius J Schmidt1, Stefanie M Bode-Böger2, Jens Martens-Lobenhoffer2, Marius M Hoeper3, Jan T Kielstein4.   

Abstract

Entities:  

Keywords:  COVID-19; PIRRT; remdesivir

Mesh：

Substances：

Year:  2021        PMID： 34301737      PMCID： PMC8455057          DOI： 10.2215/CJN.17601120

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   10.614


× No keyword cloud information.
  5 in total

Review 1.  Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19.

Authors:  Meagan L Adamsick; Ronak G Gandhi; Monique R Bidell; Ramy H Elshaboury; Roby P Bhattacharyya; Arthur Y Kim; Sagar Nigwekar; Eugene P Rhee; Meghan E Sise
Journal:  J Am Soc Nephrol       Date:  2020-06-08       Impact factor: 10.121

2.  Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19.

Authors:  Massimo Tempestilli; Priscilla Caputi; Valeria Avataneo; Stefania Notari; Olindo Forini; Laura Scorzolini; Luisa Marchioni; Tommaso Ascoli Bartoli; Concetta Castilletti; Eleonora Lalle; Maria R Capobianchi; Emanuele Nicastri; Antonio D'Avolio; Giuseppe Ippolito; Chiara Agrati
Journal:  J Antimicrob Chemother       Date:  2020-10-01       Impact factor: 5.790

3.  Hemoadsorption eliminates remdesivir from the circulation: Implications for the treatment of COVID-19.

Authors:  Paul Biever; Dawid L Staudacher; Michaela J Sommer; Hannah Triebel; Merja A Neukamm; Christoph Bode; Alexander Supady; Achim Lother
Journal:  Pharmacol Res Perspect       Date:  2021-04

4.  Hemofiltration with the Seraph® 100 Microbind® Affinity filter decreases SARS-CoV-2 nucleocapsid protein in critically ill COVID-19 patients.

Authors:  Dawn Mattoon; Andrew J Ball; Jan T Kielstein; Dan-Nicolae Borchina; Thomas Fühner; Soyoon Hwang
Journal:  Crit Care       Date:  2021-06-01       Impact factor: 9.097

Review 5.  Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19.

Authors:  Sarah C J Jorgensen; Razieh Kebriaei; Linda D Dresser
Journal:  Pharmacotherapy       Date:  2020-06-28       Impact factor: 6.251
  5 in total
  3 in total

1.  Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients.

Authors:  E Leegwater; D J A R Moes; L B E Bosma; T H Ottens; I M van der Meer; C van Nieuwkoop; E B Wilms
Journal:  Antimicrob Agents Chemother       Date:  2022-06-01       Impact factor: 5.938

2.  Safety and efficacy of the Seraph® 100 Microbind® Affinity Blood Filter to remove bacteria from the blood stream: results of the first in human study.

Authors:  Gabriele Eden; Julius J Schmidt; Stefan Büttner; Philipp Kümpers; Carsten Hafer; Alexandros Rovas; Benjamin Florian Koch; Bernhard M W Schmidt; Jan T Kielstein
Journal:  Crit Care       Date:  2022-06-17       Impact factor: 19.334

3.  A Multicenter Evaluation of the Seraph 100 Microbind Affinity Blood Filter for the Treatment of Severe COVID-19.

Authors:  Stephen A Chitty; Sarah Mobbs; Brian S Rifkin; Steven W Stogner; Michael S Lewis; Jaime Betancourt; Jeffrey DellaVolpe; Fadi Abouzahr; Andrew M Wilhelm; Harold M Szerlip; Amay Parikh; Robert M Gaeta; Ian Rivera; Caroline Park; Benjamin Levi; George L Anesi; Karl C Alcover; Thomas B Arnold; Jeffrey T Howard; Kumar Sharma; Kathleen P Pratt; Ian J Stewart; Kevin K Chung
Journal:  Crit Care Explor       Date:  2022-03-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.